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To determine whether non-human adenovirus-specific antibodies are cross-neutralizing, rabbit and mouse anti-human
adenovirus type 5 (HAd5), anti-bovine adenovirus type 3 (BAd3), and anti-porcine adenovirus type 3 (PAd3) sera were used
in cross-virus neutralization assays. Adenovirus neutralizing antibodies were found to be virus-specific, suggesting that virus
neutralizing epitope differs significantly in HAd5, BAd3, and PAd3. To further investigate whether immunity to an HAd5-
derived vector could be circumvented by the use of non-human adenoviruses in vivo, mice were first immunized either
intranasally or intraperitoneally with HAd5, BAd3, PAd3, or BAd3 1 PAd3, and after development of adenovirus-specific
antibodies, animals were inoculated with the HAd5 recombinant (AdCA36lacZ) containing the bacterial b-galactosidase gene
under the control of murine cytomegalovirus immediate-early promoter. Virus-inoculated animals developed virus-specific
IgG and IgA antibodies. LacZ expression in animals initially primed with HAd5 was significantly reduced (P , 0.05),
suggesting that the immune response against the vector could prevent the transgene expression following subsequent
inoculation of the same vector, whereas LacZ expression in mice initially primed with BAd3, PAd3, or BAd3 1 PAd3 was
significantly higher (P . 0.05) than that obtained in HAd5-primed animals. Our results suggest that HAd5-, BAd3-, or
PAd3-based vectors may be used sequentially for human gene therapy or vaccine production as a means to avoid immunity
to the vector. © 2000 Academic Press
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aINTRODUCTION
Adenovirus-based vectors have been demonstrated to
be excellent vehicles for expressing foreign genes into
mammalian cells (Berkner, 1988; Graham, 1990; Graham
and Prevec, 1992; Mittal et al., 1994; Rasmussen et al.,
1999). Several features of adenovirus biology have made
such vectors potential candidates in a number of gene
therapy applications. For example adenoviruses are ca-
pable of transferring genes to a broad spectrum of both
replicating and quiescent cell types. Moreover, adenovi-
rus vectors can easily be grown to high titers and high
levels of transgene expression can be obtained.
It has been clearly demonstrated that E1-deleted rep-
lication-defective human adenovirus (HAd) vectors are
capable of expressing viral early and late genes of a
magnitude sufficient to stimulate cellular and humoral
immune response (Smith et al., 1993; Korzasky et al.,
1994; Yang et al., 1994, 1995; Barr et al., 1995; Dai et al.,
995) leading to removal of vector-infected cells. The
ellular immune response eliminates the target cells
xpressing viral and transgene products, whereas neu-
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159ralizing antibodies significantly inhibit virus uptake fol-
owing readministration of the same vector (Setoguchi et
l., 1994; Barr et al., 1995; Dong et al., 1996; Walter et al.,
1996). This is mainly responsible for the rapid loss of
transgene expression in experimental animals (Crystal,
1995; Kass-Eisler et al., 1996). In addition to E1 deletion,
E2a, E2b, and E4 deletions resulted in minimal adenovi-
ral late gene expression without drastic improvement in
the duration of transgene expression (Engelhardt et al.,
1994; Yang et al., 1995; Kafri et al., 1998). Subsequently,
helper-dependent vectors that have a large portion of the
genome deleted were developed (Fisher et al., 1996;
Kochanek et al., 1996; Morsy et al., 1998). Inoculation of
animals with an HAd vector having all viral coded se-
quences deleted resulted in improved safety and pro-
longed expression of the transgene (Kochanek et al.,
1996; Morsy et al., 1998). The first inoculation of animals
with any type of adenovirus vector would result in an
immune response against the vector. Furthermore, the
presence of preexisting neutralizing antibodies may
even preclude a single successful administration of HAd
vectors in humans.
Recently, strategies to overcome the immune re-
sponse including immunomodulation (Kay et al., 1995;
Smith et al., 1996; McLane et al., 1997) and induction of
immunotolerance (Ilan et al., 1998; Kagami et al., 1998)
have been used to achieve somewhat satisfactory re-
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160 MOFFATT ET AL.sults. The other strategy to circumvent adenovirus-spe-
cific neutralizing immunity is to switch the serotype of the
adenovirus vector (Kass-Eisler et al., 1996). The HAd
serotypes have been placed into six subgroups based on
cross-virus neutralization (Hierholzer, 1992; Shenk, 1996).
To extend the range of adenovirus-based vectors as
well as ameliorate the neutralizing immune response, a
number of non-human adenoviruses such as bovine ad-
enovirus type 3 (BAd3) (Mittal et al., 1995a), canine ade-
novirus type 2 (CAd2) (Klonjkowski et al., 1997), ovine
adenovirus vector (Hoffman et al., 1999), and porcine
adenovirus type 3 (PAd3) (Reddy et al., 1999) have been
developed to supplement HAd vectors for gene therapy.
Our preliminary investigation together with the work
done by others (Klonjkowski et al., 1997; Rasmussen et
al., 1999) has shown that these non-human adenoviruses
could infect human cells. We speculated that there may
not be significant cross-reacting virus-neutralizing anti-
bodies among human and non-human adenoviruses.
The focus of this study was to determine whether
HAd5-specific neutralizing immunity can be circum-
vented using non-human adenovirus. Despite significant
cross-reacting enzyme-linked immunosorbent assay
(ELISA) antibodies, there was no cross-over with respect
to neutralization between human and non-human adeno-
viruses. Furthermore, LacZ expression in mice initially
primed with BAd3, PAd3, or BAd3 1 PAd3 was signifi-
cantly higher (P , 0.05) than that obtained in human
adenovirus type 5 (HAd5)-primed animals. We hypothe-
size that human and non-human adenoviruses could be
FIG. 1. Cross-reacting ELISA IgG antibodies among HAd5, BAd3, and
PAd3. Hyperimmune anti-HAd5, anti-BAd3, and anti-PAd3 sera raised in
rabbits were used to detect levels of virus-specific or cross-reacting
antibodies by ELISA. Each point represents the mean value from two
different experiments. The striped, black, and hatched bars represent
HAd5-, BAd3-, and PAd3-specific titers, respectively.used in sequential administration to circumvent the vec-
tor-specific neutralizing immune response.
RESULTS
Antibody cross-reactivity among HAd5, BAd3, and
PAd3 using hyperimmune antisera. To determine the lev-
els of cross-reacting antibodies among adenoviruses,
hyperimmune anti-HAd5, anti-BAd3, and anti-PAd3 sera
raised in rabbits were initially tested for the presence of
cross-reacting antibodies by ELISA. The highest ELISA
antibody titers were obtained with the homologous anti-
gen and antiserum combinations (HAd5 and anti-HAd5
serum, BAd3 and anti-BAd3 serum, and PAd3 and anti-
PAd3 serum) (Fig. 1). The titer of the anti-HAd5 serum
against BAd3 and PAd3 was 35 and 25%, respectively,
compared to that obtained with the homologous antigen.
Similarly, the titer of anti-BAd3 serum against HAd5 and
PAd3 was 24 and 28%, respectively, compared to that
obtained with the homologous antigen, whereas the titer
of anti-PAd3 serum against HAd5 and BAd3 was 9 and
36%, respectively, compared to that obtained with the
homologous antigen.
Virus neutralizing antibodies among HAd5, BAd3, and
PAd3. Since the hyperimmune sera showed high levels
of adenovirus cross-reacting ELISA antibodies among
HAd5, BAd3, and PAd3, we were interested in determin-
ing whether cross-reacting antibodies were virus-neu-
tralizing by performing in vitro virus neutralizing assays.
There was a significant level of virus neutralizing activity
mainly with the homologous virus and antiserum (Table
1). The virus neutralizing antibody titers using hyperim-
mune sera were 6400, 3200, and 3200 for HAd5/anti-
HAd5, BAd3/anti-BAd3, and PAd3/anti-PAd3, respectively.
We then determined whether immunization of mice
would also raise neutralizing antibodies and whether
TABLE 1
Cross-Neutralizing Antibody Titers among Human and Non-Human
Adenoviruses Using Rabbit Hyperimmune Antiseruma
Hyperimmune
serum
Virus
HAd5 BAd3 PAd3b
Anti-HAd5 6400 50 50
Anti-BAd3 50 3200 100
Anti-PAd3 100 50 3200
a Hyperimmune anti-HAd5, anti-BAd3, and anti-PAd3 sera raised in
abbits were used to detect levels of virus-specific or cross-neutralizing
ntibodies by virus-neutralizing assays. Neutralizing antibody titers are
xpressed as the highest reciprocal serum dilution resulting in reduc-
ion of virus plaque formation or TCID50 by at least 50%. Titers are
expressed as mean value from two experiments.
b TCID50 was used for determining the titer of PAd3 on ST cells.these would cross-react. There was significant virus neu-
tralizing activity mainly with the homologous virus and
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161NON-HUMAN ADENOVIRUSES IN GENE THERAPYantiserum. The virus neutralizing antibody titers using
intrapenitoneally (ip) immunized mice sera were 3200,
3200, and 3200 for HAd5/anti-HAd5, BAd3/anti-BAd3, and
PAd3/anti-PAd3, respectively (Table 2), and those for in-
tranasally (i.n.) immunized mice were 1600, 1600, and
1600 for HAd5/anti-HAd5, BAd3/anti-BAd3, and PAd3/
anti-PAd3, respectively (Table 3).
Antibody cross-reactivity among HAd5, BAd3, and
PAd3 in mice. The above results obtained with rabbit
hyperimmune and mouse anti-HAd5, anti-BAd3, and anti-
PAd3 sera regarding the presence of adenovirus cross-
reacting ELISA antibodies and cross-neutralizing anti-
bodies among HAd5, BAd3, and PAd3 suggested that the
problem in adenovirus-based gene delivery posed by
preexisting virus-specific neutralizing antibodies could
be overcome by using different adenovirus vectors. In
order to prove this hypothesis, mice were immunized i.n.
or ip with HAd5, BAd3, or PAd3 or a combination of BAd3
and PAd3, and the serum samples were collected at 0
and 28 days postinfection. The serum samples were
tested for the presence of cross-reacting IgG and IgA
antibodies by ELISA. The choice of the route of inocula-
tion was based on the fact that i.n. inoculation leads to a
stronger secretory IgA response, whereas ip inoculation
results in a stronger systemic immune response (Collins
et al., 1990; Kanesaki et al., 1991; Meitin et al., 1994; Papp
et al., 1997). The serum samples from ip-inoculated ani-
mals collected at 28 days postinfection had the highest
titers of adenovirus IgG antibodies in the homologous
antigen and antiserum combinations (HAd5 and anti-
HAd5 serum, BAd3 and anti-BAd3 serum, and PAd3 and
anti-PAd3 serum) (Fig. 2A). In i.n.-inoculated mice, how-
ever, the titer of adenovirus IgG antibodies in the homol-
ogous antigen and antiserum combinations was lowest
for HAd5 followed by BAd3 and PAd3 (Fig. 2B). It was
interesting to observe that the BAd3 1 PAd3 combination
TABLE 2
Cross-Neutralizing Antibody Titers among Human and Non-Human
Adenoviruses Using Antiserum from ip-Immunized Micea
Mouse antiserum
Virus
HAd5 BAd3 PAd3b
Anti-HAd5 3200 50 50
Anti-BAd3 50 3200 100
Anti-PAd3 50 50 3200
a Anti-HAd5, anti-BAd3, and anti-PAd3 sera obtained from ip-immu-
ized mice at 28 days p.i. were used to detect levels of virus-specific or
ross-neutralizing antibodies by virus-neutralizing assays. Neutralizing
ntibody titers are expressed as the highest reciprocal serum dilution
esulting in reduction of virus plaque formation or TCID50 by at least
0%. Titers are expressed as the mean value from two experiments.
b TCID50 was used for determining the titer of PAd3 on ST cells.showed an HAd5 cross-reacting IgG antibody titer com-
parable to that obtained with only BAd3 inoculation. Mice
5inoculated ip with HAd5 showed approximately 30 and
7% cross-reacting IgG antibodies with BAd3 and PAd3,
respectively, whereas animals inoculated i.n. with HAd5
demonstrated 44 and 36% cross-reacting IgG antibodies
with BAd3 and PAd3, respectively. Similarly, mice inocu-
lated ip with BAd3 showed approximately 25 and 11%
cross-reacting IgG antibodies with HAd5 and PAd3, re-
spectively, whereas animals inoculated i.n. with BAd3
demonstrated 19 and 30% cross-reacting IgG antibodies
with HAd5 and PAd3, respectively. Furthermore, mice
inoculated ip with PAd3 showed approximately 11 and
23% cross-reacting IgG antibodies with HAd5 and BAd3,
respectively, whereas animals inoculated i.n. with PAd3
demonstrated approximately 19 and 28% cross-reacting
IgG antibodies with HAd5 and BAd3, respectively.
Similarly, we examined the level of adenovirus cross-
reactive IgA ELISA antibodies in the serum samples of
mice inoculated with HAd5, BAd3, or PAd3 (Fig. 3). The
serum samples from mice inoculated ip with HAd5
showed approximately 36 and 35% cross-reacting IgA
antibodies with BAd3 and PAd3, respectively, whereas
animals inoculated i.n. with HAd5 demonstrated 46 and
13% cross-reacting IgA antibodies with BAd3 and PAd3,
respectively. Similarly, mice inoculated ip with BAd3
showed approximately 25 and 11% cross-reacting IgA
antibodies with HAd5 and PAd3, respectively, whereas
animals inoculated i.n. with BAd3 demonstrated 14 and
15% cross-reacting IgA antibodies with HAd5 and PAd3,
respectively. Finally, mice inoculated ip with PAd3
showed approximately 11 and 30% cross-reacting IgA
antibodies with HAd5 and BAd3, respectively, whereas
animals inoculated i.n. with PAd3 demonstrated approx-
imately 29 and 38% cross-reacting IgA antibodies with
HAd5 and BAd3, respectively.
Levels of b-galactosidase (b-gal) expression following
dCA36lacZ inoculation in mice having HAd5-, BAd3-, or
Ad3-specific antibodies. Initially, to determine the kinet-
cs of LacZ expression, mice (two animals/group) were
TABLE 3
Cross-Neutralizing Antibody Titers among Human and Non-Human
Adenoviruses Using Antiserum from i.n.-Immunized Micea
Mouse antiserum
Virus
HAd5 BAd3 PAd3b
Anti-HAd5 1600 50 50
Anti-BAd3 50 1600 50
Anti-PAd3 50 50 1600
a Anti-HAd5, anti-BAd3, and anti-PAd3 sera obtained from i.n.-immu-
ized mice at 28 days p.i. were used to detect levels of virus-specific or
ross-neutralizing antibodies by virus-neutralizing assays. Neutralizing
ntibody titers are expressed as the highest reciprocal serum dilution
esulting in reduction of virus plaque formation or TCID50 by at least
0%. Titers are expressed as the mean value from two experiments.
b TCID50 was used for determining the titer of PAd3 on ST cells.
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162 MOFFATT ET AL.inoculated i.n. or ip with 5 3 108 PFU of AdCA36lacZ and
at 0.5, 1, 2, 3, and 4 days postinoculation, the liver,
spleen, kidneys, lungs, and trachea were collected to
monitor LacZ expression. In i.n.-inoculated animals sig-
nificantly higher levels of LacZ expression were obtained
in the lungs and trachea than in the liver, spleen, and
kidneys and the maximum LacZ expression was ob-
served at day 1 postinoculation (data not shown). In
ip-inoculated animals, significantly higher levels of LacZ
expressions were obtained in the liver, spleen, and lungs
than in kidneys and trachea, and the maximum expres-
sion was also observed at day 1 postinoculation (data
not shown). Therefore in subsequent experiments, mice
inoculated i.n. or ip with AdCA36lacZ were sacrificed at
day 1 postinoculation and the lungs and trachea were
collected from i.n.-inoculated animals, whereas the liver,
spleen, and lungs were collected from ip-inoculated an-
imals to monitor LacZ expression.
To determine the levels of transgene expression
from an HAd vector in the presence of HAd5-, BAd3-,
or PAd3-specific antibodies, mice primed i.n. or ip with
PBS, HAd5, BAd3, PAd3, or BAd3 1 PAd3 were inoc-
ulated with AdCA36lacZ by the same route they were
primed with. One day after AdCA36lacZ inoculation,
the spleen, liver, and lung from ip-inoculated mice and
FIG. 2. Cross-reacting ELISA IgG antibodies among HAd5, BAd3, and
ip or (B) i.n. with PBS, HAd5, BAd3, PAd3, or BAd3 1 PAd3. Serum sampl
the levels of virus-specific or cross-reacting IgG antibodies by ELISA. Ea
and hatched bars represent HAd5-, BAd3-, and PAd3-specific titers, rethe lungs and trachea from i.n.-inoculated mice were
collected and b-gal expression in tissues was quanti-
2
lated by LacZ assay. In ip-inoculated PBS-primed
ice, expression of LacZ was approximately 2.42 3
07, 8.2 3 106, and 1.3 3 106 units/g in the spleen, liver,
nd lungs, respectively (Fig. 4A), whereas in i.n.-inoc-
lated PBS-primed mice, LacZ expression was approx-
mately 1.2 3 107 and 1.04 3 106 units/g in the lungs
nd trachea, respectively (Fig. 4B). In ip-inoculated
Ad5-primed mice, expression of LacZ in the spleen,
iver, and lungs was dramatically reduced to approxi-
ately 0.04, 0.01, and 0.08%, respectively, of the levels
btained with ip-inoculated PBS-primed animals,
hereas in i.n.-inoculated HAd5-primed mice, LacZ
xpression in the lungs and trachea was approxi-
ately 0.08 and 0.01%, respectively, of the levels ob-
ained with i.n.-inoculated PBS-primed animals. On the
ther hand, in ip-inoculated BAd3-primed mice, ex-
ression of LacZ in the spleen, liver, and lungs was
pproximately 30, 18, and 8%, respectively, of the lev-
ls obtained with ip-inoculated PBS-primed animals,
hereas in i.n.-inoculated BAd3-primed mice, LacZ
xpression in the lungs and trachea was approxi-
ately 8 and 5%, respectively, of the levels obtained
ith i.n.-inoculated PBS-primed animals. In ip-inocu-
ated PAd3-primed mice, expression of LacZ in the
pleen, liver, and lungs was approximately 35, 20, and
6- to 8-week-old Balb/c mice (four animals/group) were immunized (A)
e collected at 0 and 28 days postinoculation and analyzed to determine
nt represents the mean value for four animals 6 SD. The striped, black,
ely.PAd3.
es wer%, respectively, of the levels obtained with ip-inocu-
ated PBS-primed animals, whereas in i.n.-inoculated
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163NON-HUMAN ADENOVIRUSES IN GENE THERAPYPAd3-primed mice, LacZ expression in the lungs and
trachea was approximately 13 and 10%, respectively, of
the levels obtained with i.n.-inoculated PBS-primed
animals. In ip-inoculated BAd3 1 PAd3-primed mice,
xpression of LacZ in the spleen, liver, and lungs was
pproximately 21, 12, and 6%, respectively, of the levels
btained with ip-inoculated PBS-primed animals,
hereas in i.n.-inoculated BAd3 1 PAd3-primed mice,
acZ expression in the lungs and trachea was approx-
mately 5 and 4%, respectively, of the levels obtained
ith i.n.-inoculated PBS-primed animals. These results
uggest that there was significant (P , 0.05) inhibi-
tion of LacZ expression in HAd5-primed mice. Levels
of LacZ expression in BAd3-, PAd3-, or BAd3 1 PAd3-
rimed mice were reduced compared to PBS-primed
nimals but significantly higher (P , 0.05) than those
f HAd5-primed mice. BAd3-, PAd3-, BAd3 1 PAd3-
rimed mice showed approximately 7200-, 6000-, and
000-fold, 8500-, 640-, and 200-fold, and 5200-, 4000-,
nd 800-fold higher LacZ expression in the spleen,
iver, and lung, respectively, than ip-inoculated HAd5-
rimed mice, whereas in BAd3-, PAd3-, or BAd3 1
Ad3-primed mice, there was approximately 2000- and
00-fold, 3000- and 1000-fold, and 1200- and 425-fold
igher LacZ expression in the lung and trachea, re-
FIG. 3. Cross-reacting ELISA IgA antibodies among HAd5, BAd3, and
ip or (B) i.n. with PBS, HAd5, BAd3, PAd3, or BAd3 1 PAd3. Serum sampl
the levels of virus-specific or cross-reacting IgA antibodies by ELISA. Ea
and hatched bars represent HAd5-, BAd3-, and PAd3-specific titers, repectively, than in i.n.-inoculated HAd5-primed ani-
als. PDISCUSSION
Recombinant adenovirus vectors are excellent vehi-
les for gene therapy due to their high levels of trans-
uction efficiency in a variety of cell types. All adenovirus
ectors (both replication defective and gutless) result in
ector-specific immune responses that significantly re-
uce transgene expression following a second adminis-
ration of the same vector. Some of the strategies for
ircumvention of the immune response against the vec-
or include immunosuppression (Kay et al., 1995; Smith et
l., 1996; Yang et al., 1996; McLane et al., 1997; Guibinga
et al., 1998), use of other HAd serotypes (Kaier and
Wigand, 1986; Hierholzer, 1992; Adam et al., 1995; Mack
et al., 1997), or alteration of the immunodominant capsid
epitopes (Roy et al., 1998). Since preexisting immunity to
adenoviruses is widespread in humans, it may inhibit
transgene expression even with the first inoculation of
the HAd vector. A number of non-human adenoviruses as
vectors have been developed (Mittal et al., 1995a; Klon-
kowski et al., 1997; Reddy et al., 1999; Hoffman et al.,
999) in the past few years as potential supplements to
he HAd vectors. Here we demonstrate that non-human
denoviruses may be useful in circumventing HAd neu-
ralizing antibody response.
6- to 8-week-old Balb/c mice (four animals/group) were immunized (A)
e collected at 0 and 28 days postinoculation and analyzed to determine
t represents the mean value for four animals 6 SD. The striped, black,
ely.PAd3.
es werAlthough hyperimmune anti-HAd5, anti-BAd3, and anti-
Ad3 sera had significant cross-reacting ELISA antibod-
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164 MOFFATT ET AL.ies among HAd5, BAd3, and PAd3, these antisera were
found to neutralize only the homologous virus efficiently.
Similarly, sera from mice immunized with HAd5, BAd3, or
PAd3 exhibited cross-reacting ELISA antibodies among
HAd5, BAd3, and PAd3, but neutralizing antisera were
found only in the homologous antigen–antiserum combi-
nations, suggesting that the virus neutralizing epitope
differs significantly in these three adenoviruses. As ex-
pected, mice immunized with HAd5, BAd3, or PAd3 had
adenovirus cross-reactive IgG and IgA ELISA antibodies.
In mice having preexisting HAd5-specific antibodies,
there was severe inhibition in transgene expression
when the mice were inoculated with AdCA36lacZ. Similar
results have been obtained with readministration of the
same vector (Mittal et al., 1993; Mack et al., 1997; Mc-
Clane et al., 1997), whereas in mice having preexisting
BAd3-, PAd3-, or BAd3 1 PAd3-specific immune re-
sponse, there was approximately 8000-, 5000-, and 6000-
fold higher transgene expression than in animals having
a preexisting HAd5-specific immune response. LacZ ex-
pression in animals with preexisting anti-BAd3, anti-
PAd3, or anti BAd3 1 PAd3 antibodies following inocu-
lation with the AdCA36lacZ recombinant seems to be
FIG. 4. Level of b-gal expression by AdCA36lacZ in primed mice with
nimals/group) were immunized ip with PBS, HAd5, BAd3, PAd3, or BA
-week old Balb/c mice (four animals/group) were immunized i.n. with
dCA36lacZ on day 28. One day following AdCA36lacZ inoculation, the
rom i.n.-inoculated mice were collected and analyzed for b-gal express
black, and hatched bars in (A) represent the spleen, liver, and lung, r
trachea, respectively.somewhat lower in the i.n.- than in the ip-inoculated
animals, suggesting the importance of secretory IgA incross-virus neutralization. These results signify the use-
fulness of non-human adenovirus vectors for human
gene therapy and for developing adenovirus-based re-
combinant vaccines. We did not address the effect of
cross-reacting cell-mediated immune response in dimin-
ishing transgene expression.
Improved second and third generations of HAd vectors
with diminished or no viral protein expression would
enhance the effectiveness of transgene expression (En-
gelhardt et al., 1994; Kay et al., 1995; Yang et al., 1995;
Kochanek et al., 1996; Morsy et al., 1998); however, they
would induce a virus-specific neutralizing immune re-
sponse. Readministering the same vector, therefore, is
unlikely to be effective. Since HAd5, BAd3, and PAd3
neutralizing antibodies are not cross-neutralizing, it is
hypothesized that vectors based on these adenoviruses
would be effective when administered sequentially. All
these viruses would also induce a virus-specific neutral-
izing immune response, thereby diminishing transgene
expression on subsequent inoculations with the same
vector. Therefore, it is likely that alternative use of HAd5,
BAd3, PAd3, and other vectors may be useful in circum-
venting virus-specific immune response and in increas-
uman or non-human adenovirus. (A) 6- to 8-week-old Balb/c mice (four
Ad3 on day 0 and inoculated ip with AdCA36lacZ on day 28. (B) 6- to
Ad5, BAd3, PAd3, or BAd3 1 PAd3 on day 0 and inoculated i.n. with
, liver, and lungs from ip-inoculated mice and the lungs and tracheae
ch point represents the mean value for four animals 6 SD. The striped,
ively. The hatched and striped bars in (B) represent the lung and theeither h
d3 1 P
PBS, H
spleen
ion. Eaing the duration of transgene expression.
Infection of human cells by non-human adenovirus
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165NON-HUMAN ADENOVIRUSES IN GENE THERAPYvectors leading to expression of the transgene has al-
ready been demonstrated (Mittal et al., 1995a; Klonj-
kowski et al., 1997; Rasmussen et al., 1999), but the
efficiency and duration of transgene expression still
need to be determined. Advantages of both HAd and
non-HAd could be combined to develop chimeric vectors
to circumvent the adenovirus-specific immunity and to
increase the efficiency of transduction for certain organs
or cell types.
MATERIALS AND METHODS
Cell lines and viruses. Bovine (MDBK), porcine (ST),
and human (293) cell lines were grown as monolayer
cultures in Eagle’s minimum essential medium (MEM)
supplemented with 5–10% Fetal Clone III (Hyclone, Inc.)
and 50 mg/ml gentamycin. HAd5, BAd3, and PAd3 were
rown on 293, MDBK, and ST cells, respectively. HAd5
nd BAd3 were titrated by plaque assay on 293 and
DBK cells, respectively, whereas PAd3 was titrated by
CID50 on ST cells. For raising hyperimmune antisera in
rabbits and for inoculation of mice, viruses were purified
by cesium chloride density-gradient centrifugation (Gra-
ham and Prevec, 1991). The recombinant human adeno-
virus AdCA36lacZ (Addison et al., 1997), containing the
bacterial b-gal gene in the E1 region under the control of
ouse cytomegalovirus promoter, was a kind gift from
r. Frank Graham, Departments of Biology and Pathol-
gy, McMaster University, Hamilton, Ontario, Canada.
dCA36lacZ was also grown and titrated on 293 cells.
Animals. Three- to 4-week-old New Zealand white rab-
its were purchased from Covance Research Products
nc. (Philadelphia, PA) and 8- to 10-week-old female
alb/c mice were purchased from Harlan Sprague–Daw-
ey (Indianapolis, IN). Animals were fed and watered
ormally until the end of the experiment.
Production of hyperimmune adenovirus antisera in
abbits. Two milligrams of cesium chloride density-gra-
ient-purified preparations of HAd5, BAd3, or PAd3 in 0.5
l phosphate-buffered saline containing Mg21 and Ca21
(PBS11) (0.137 M NaCl, 8 mM Na2HPO4, 1.5 mM KH2PO4,
.7 mM KCl, 1 mM MgCl2, 1 mM CaCl2) was mixed
horoughly with an equal volume of Freund’s complete
djuvant and the mixture was injected intramuscularly
im) into one New Zealand white rabbit per virus. At 3
eeks following the first injection, 1 mg of each purified
irus preparation was emulsified with an equal volume of
reund’s incomplete adjuvant and injected im into each
abbit. The animals were further boosted 2 weeks later
nd were bled under anesthesia 10 days after the last
njection. The development of anti-HAd5, anti-BAd3, and
nti-PAd3 antibodies was monitored by ELISA.
Mice inoculation. Mice were randomly grouped into 10
roups (four animals/group). Five groups were anesthe-ized with ketamine/xylazine and inoculated i.n. with 50
ml of PBS (as a control) or purified preparations contain-ing 5 3 108 PFU each of HAd5, BAd3, or PAd3 or a
combination of BAd3 and PAd3 on day 0. Subsequently,
on day 28, all animals were inoculated i.n. with 5 3 108
PFU of AdCA36lacZ. The other 5 groups were inoculated
ip with 200 ml of PBS or 2.5 3 108 PFU each of HAd5,
BAd3, and PAd3 or a combination of BAd3 and PAd3 on
day 0. Subsequently, on day 28, all animals were inocu-
lated ip with 5 3 108 PFU of AdCA36lacZ. All animals
were euthanized with an excess of ketamine/xylazine on
day 29, liver, spleen, and lungs were collected from mice
inoculated ip, and lungs and tracheae were collected
from mice inoculated i.n. These tissues were used to
measure the expression of LacZ by b-gal assay. The
erum samples were collected on days 0 and 28 to
xamine the development of virus-specific antibodies by
LISA and virus neutralization assays.
b-galactosidase assay. The technique was modified
from that described previously (Aggarwal et al., 1999).
Tissues obtained from mice were weighed and sus-
pended in 1 ml of 250 mM Tris–HCl (pH 7.8) containing 1
mM phenylmethylsulfonyl fluoride (PMSF) and then ho-
mogenized with a tissuemizer. NP-40 was added to a
final concentration of 0.5%, vortexed, and kept on ice for
10 min before being sonicated for 90 s with a pulse of
10 s intermittently. Sonicated samples were centrifuged
at 3800 rpm for 10 min at 4°C and the supernatant was
used for the enzymatic assay. A total of 20 ml of serially
iluted sample was added to 175 ml mercaptoethanol
solution (100 mM sodium phosphate, 50 mM 2-mercap-
toethanol, 10 mM KCl, and 1 mM MgSO4) in flat-bottomed
6 well-plates and preincubated at 37°C for 5 min. A total
f 66 ml of the substrate solution (4 g o-nitrophenyl-b-D-
galactopyranoside per liter in 100 mM sodium phos-
phate, pH 7.5) was added to each well and the plates
were incubated for 1 h at 37°C. The enzymatic reaction
was stopped by adding 86 ml of 1 M Na2CO3 solution.
The optical density (OD) of each well was measured at
420 nm spectrometrically using an ELISA reader (Molec-
ular Devices, Inc.). b-gal activity is expressed as units of
b-gal activity per gram of tissue using purified b-galac-
osidase as control. One unit of b-gal activity is equal to
he amount of ONPG released per minute at 37°C.
ELISA. The serum samples obtained from rabbits and
mice were used to detect virus-specific IgG and IgA
antibodies by ELISA as previously described (Mittal et
al., 1995b). Ninety-six-well microtiter plates were coated
with purified preparations of HAd5, BAd3, or PAd3 and
incubated with serial dilutions of either mouse or rabbit
serum. Horseradish peroxidase (HRP)-conjugated goat
anti-mouse IgG (Bio-Rad) or IgA (Southern Biotechnology
Associates, AL) was used as secondary antibody to
detect IgG or IgA antibody, respectively, in mouse sera.
Similarly, HRP-conjugated goat anti-rabbit IgG (Bio-Rad)
was used to detect IgG antibodies in rabbit sera. The OD
was read at a dual wavelength of 490–650 nm spectro-
metrically and values represent the means 6 SD from
a
a
B
2
e
p
P
d
s
m
166 MOFFATT ET AL.four animals. The inverse of the highest dilution of sam-
ples with an OD reading of at least the mean 1 2 SD
bove negative control sera was taken as the ELISA
ntibody titer.
Virus neutralization assays. Heat-inactivated HAd5,
Ad3, and PAd3 hyperimmune antisera or sera from mice
8 days postinoculation (p.i.) were tested for the pres-
nce of neutralizing antibodies in assays as described
reviously (Mittal et al., 1995b). Approximately 100 PFU or
TCID50 of HAd5, BAd3, or PAd3 was incubated with serial
dilutions of HAd5, BAd3, or PAd3 antiserum for 1 h at
37°C in a total volume of 100 ml. A total of 200 ml of
BS11 was added to the serum/virus mixture. The mix-
ture was allowed to adsorb onto appropriate cells for 1 h
and then 293 or MDBK monolayers were covered with an
agarose overlay (13 MEM, 0.5% agarose, 5% Fetal Clone
III, 0.05% yeast extract), whereas ST monolayers were
covered with MEM containing 2% Fetal Clone III. Plaques
were counted 10–12 days later, whereas TCID50 was
etermined 7 days after infection. The highest reciprocal
erum dilution resulting in reduction of virus plaque for-
ation or TCID50 by at least 50% was considered the
virus neutralization antibody titer.
Statistical analysis. Statistical analysis of the data was
performed using Student’s t distribution. Significance
was set at P , 0.05.
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